Enfortumab Vedotin + Pembrolizumab for Bladder Cancer

This trial aims to evaluate the effectiveness of combining two drugs, enfortumab vedotin (an antibody-drug conjugate) and pembrolizumab (an immunotherapy), in treating muscle-invasive bladder cancer. Researchers seek to determine if this drug combination can preserve the bladder more effectively than the standard chemoradiotherapy treatment. Individuals with muscle-invasive bladder cancer that remains confined to the bladder might be suitable candidates, particularly if they are exploring alternatives to bladder removal surgery. As a Phase 3 trial, this study serves as the final step before potential FDA approval, offering participants the opportunity to contribute to a treatment that could soon become widely available.

The trial information does not specify if you need to stop taking your current medications. However, if you are currently receiving treatment for an active infection or have uncontrolled diabetes, you may not be eligible to participate.

Research has shown that using enfortumab vedotin and pembrolizumab together may help treat bladder cancer, with generally manageable side effects. Studies have found this combination effective, with most side effects not severe.

In one study, patients with advanced bladder cancer lived an average of 33.8 months when treated with these drugs. About 64.5% of patients responded well to the treatment. While side effects occurred, they were usually not serious enough to outweigh the benefits.

Researchers are excited about Enfortumab Vedotin combined with Pembrolizumab because it offers a novel approach to treating bladder cancer. Unlike traditional treatments like chemotherapy and radiation, Enfortumab Vedotin is an antibody-drug conjugate that specifically targets cancer cells, delivering a potent cell-killing agent directly to them. Pembrolizumab, on the other hand, is an immunotherapy that helps the immune system recognize and fight cancer cells more effectively. Together, these treatments have the potential to improve outcomes by directly attacking cancer cells while also boosting the body's own defenses against the disease.

This trial will compare the effectiveness of enfortumab vedotin combined with pembrolizumab against concurrent chemoradiotherapy for bladder cancer. Studies have shown that enfortumab vedotin with pembrolizumab can be highly effective against bladder cancer. Specifically, research indicates that patients can live up to 34 months, longer than with other treatments. This drug combination has also shrunk tumors in 68% of patients. Additionally, these treatments have proven effective even in patients with advanced bladder cancer. These findings suggest that this combination could be promising for treating muscle-invasive bladder cancer.¹²³⁵⁶